Abstract：Objective: To investigate the mutation status and clinical significance of epidermal growth factor receptor (EGFR) gene in the different types of samples from nonsmall cell lung cancer (NSCLC)patients. Methods: ArmsQPCR and Super ArmsQPCR were used to detect the mutation status of EGFR gene in paraffin tissues, cytological smears and peripheral blood of NSCLC, respectively. The correlation between EGFR, Exon 19 deletion (E19DEL), Exon 21 L858R point mutation (E21L858R) and clinical characteristics of patients were analyzed. Results: The mutation rate of EGFR in 705 NSCLC patients was 52.06% (367/705), which was related to gender, age and sample type of patients. The mutation rate of female patients(67.69%)was significantly higher than that of male (38.68%,χ2=59.06, P 60 years old (48.93%,χ2=5.45, P60 years old (22.01%,χ2=4.31,P<0.05).The mutation rate of E21L858R was 39.78% (146/367), the mutation rate of female patients (28.62%) was significantly higher than that of male patients (13.95%,χ2=22.95, P<0.01), the mutation rate of paraffin tissue samples (22.30%) was higher than that of cytological smears (12.70%) and peripheral blood samples(6.25%,χ2=7.47, P<0.05). Conclusion: EGFR gene mutation in different samples is different, clinicians should send optimal samples for detection.
邹琳1, 兰建云2, 宋曙2, 邵伟伟2, 李蕾1, 徐娟娟1, 胥传海2. 非小细胞肺癌患者不同类型样本EGFR基因突变分析[J]. 江苏大学学报:医学版, 2019, 29(05): 436-440,450.
ZOU Lin1, LAN Jian-yun2, SONG Su2, SHAO Wei-wei2, LI Lei1, XU Juan-juan1,XU Chuan-hai2. Analysis of EGFR gene mutations in different types of samples
from nonsmall cell lung cancer patients. Journal of Jiangsu University(Medicine Edition), 2019, 29(05): 436-440,450.
1］Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018\[J\]. CA Cancer J Clin, 2018, 68(1):7-30.［2］Torre LA, Siegel RL, Jemal A. Lung cancer statistics\[J\]. Adv Exp Med Biol, 2016, 893:1-19.［3］Han JY, Park K, Kim SW, et al. FirstSIGNAL: firstline singleagent iressa versus gemcitabine and cisplatin trial in neversmokers with adenocarcinoma of the lung\[J\]. J Clin Oncol, 2012, 30(10):1122-1128.［4］Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutationpositive nonsmallcell lung cancer (OPTIMAL,CTONG0802): a multicentre, openlabel, randomised, phase 3 study\[J\].Lancet Oncol, 2011,12 (8):735-742.［5］喻晶, 李运雷, 刘晓翌. 非小细胞肺癌患者不同类型样本中表皮生长因子受体基因突变的差异研究\[J\]. 现代检验医学杂志, 2018，33(4):31-33.［6］Buder A, Hochmair MJ, Schwab S, et al. Cellfree plasma DNAguided treatment with osimertinib in patients with advanced EGFRmutated NSCLC\[J\]. J Thorac Oncol, 2018, 13(6):821-830.［7］Tan DSW, Yom SS, Tsao MS, et al.The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutationpositive nonsmall cell lung cancer: status in 2016\[J\]. J Thorac Oncol, 2016 , 11(7): 946-963.［8］李禹龙,贺建勋,曾小莉,等.血浆游离DNA检测临床意义的研究进展\[J\].中华检验医学杂志,2019,42(4):318-322.［9］Bernabe R, Hickson N, Wallace A, et al. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer \[J\]. Eur J Cancer, 2017, 81:66-73.［10］Karachaliou N, MolinaVila MA, Rosell R. The impact of rare EGFR mutations on the treatment response of patients with nonsmall cell lung cancer\[J\]. Expert Rev Respir Med, 2015, 9(3):241-244.［11］李锐, 叶胜兵, 何燕,等. 微滴数字PCR和突变扩增阻滞系统法检测不同类型非小细胞肺癌标本及血浆标本表皮生长因子受体基因突变情况比较\[J\]. 中华病理学杂志, 2017, 46(11):764-768.［12］Tasdemir S, Taheri S, Akalin H, et al. Increased EGFR mRNA expression levels in nonsmall cell lung cancer\[J\]. Eurasian J Med, 2019, 51(2):177-185.［13］张标,杨军. 非小细胞肺癌表皮生长因子受体基因突变236例分析\[J\]. 江苏大学学报（医学版）, 2017,27(2):179-182.［14］刘春样,孙怡,高丽丽,等.139例肺癌小活检标本EGFR,ALK,ROS1基因状态分析\[J\].临床与病理杂志,2018,38(3):498-503.［15］赵丽辉,孙世珺,陈应智,等.中山市非小细胞肺癌患者EGFR基因与EML4ALK融合基因突变的统计分析\[J\]. 国际检验医学杂志, 2017, 38(18):2559-2562.［16］Shi Y, Au SK, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced nonsmallcell lung cancer of adenocarcinoma histology (PIONEER)\[J\]. J Thorac Oncol, 2014, 9(2):154-162.［17］王娜, 郑清, 孙成铭, 等. 非小细胞肺癌EGFR基因突变的表现及其与肿瘤标记物的相关性\[J\]. 现代肿瘤医学, 2016,24(19):3053-3056.
2019, Vol. 29 
